Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025. "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're ...

The pharmaceutical company Amgen is suing the Colorado Prescription Drug Affordability Board after the price of one of its ...

Learn more about whether Biogen Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...

Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety ...

Less than two weeks from now, Colorado residents looking to buy health insurance through the state’s individual marketplace will be able to choose plans, but they can’t yet see how severe the price ...

Staffing shortages in University of Colorado Hospital’s sterilization department were so acute this summer that state inspectors reported finding trays of surgical tools caked in blood and tissue that ...

Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...